Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes: a subgroup analysis from the ATMOSPHERE trial

Risk Related to Pre–Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection FractionCLINICAL PERSPECTIVE

(2016) Søren L. Kristensen et al.   Circulation-Heart Failure

Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure

(2016) John J.V. McMurray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Challenges to Data Monitoring Committees When Regulatory Authorities Intervene

(2016) Karl Swedberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Aliskiren Trial to Minimize OutcomeS in Patients with HEart failure trial (ATMOSPHERE): revised statistical analysis plan and baseline characteristics

(2015) Henry Krum et al.   EUROPEAN JOURNAL OF HEART FAILURE

Effect of Aliskiren on Postdischarge Mortality and Heart Failure Readmissions Among Patients Hospitalized for Heart Failure

(2013) Mihai Gheorghiade et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes

(2012) Hans-Henrik Parving et al.   NEW ENGLAND JOURNAL OF MEDICINE

Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOS

(2010) Henry Krum et al.   EUROPEAN JOURNAL OF HEART FAILURE

Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events

(2008)   NEW ENGLAND JOURNAL OF MEDICINE